Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 9/20 | 0.39 |
| ▸ | CDK4 | P11802 | 6/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | IKBKB | O14920 | 5/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1411782 | 0.91 | RET (0.38) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1411727 | 0.90 | IKBKB (0.46) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1411691 | 0.89 | SYK (0.38) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL3201287 | 0.89 | CDK2 (0.44) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL5140980 | 0.89 | CDK2 (0.35) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL3201699 | 0.89 | CDK2 (0.41) | NEK2CDK2CDK4CDK7CDK9 | |
| SCHEMBL3204027 | 0.85 | BRD4 (0.50) | CDK2CDK7CDK9CCNT1IGF1R | |
| SCHEMBL3192460 | 0.85 | CDK2 (0.46) | NEK2CDK2CDK4CDK7CDK9 | |
| SCHEMBL3216553 | 0.85 | PTK2 (0.45) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1412198 | 0.84 | CDK2 (0.50) | CDK2CDK4CDK7CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | claimed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | claimed |
| EP-1940846-A2 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | Cyclacel Limited (GB) | 2008-07-09 | — | — | EP | claimed |
| WO-2007042784-A2 | PYRIMIDIN-4-YL-3, 4-DIHYDR0-2H- PYRROLO [1, 2A] PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LIMITED (GB) | 2007-04-19 | — | — | WO | claimed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-1940846-A2 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | Cyclacel Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042784-A2 | PYRIMIDIN-4-YL-3, 4-DIHYDR0-2H- PYRROLO [1, 2A] PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYP2A13, NR1I3, NR3C2 | NEK2 2575/4885CDK2 577/4885CDK4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.